Cereno Scientific reaches its largest milestone to date

27 September, 2019

Cereno Scientific is in full swing preparing its Phase II study with the drug candidate CS1, aiming to initiate the study in the first half of 2020. Yesterday, the company received study approval from the regulatory authorities in Russia. The company has thus achieved its largest milestone to date. Next up is study approval in Bulgaria as well as to complete both upscaling and production of clinical trial material before the study can be initiated.

Read the full article on BioStock here.


BioStock Life Science Summit 2019-10-23 - 2019-10-24

3rd annual Anti-Fibrotic Drug Development Summit (AFDD) 2019-11-18 - 2019-11-20

Nordic-American Life Sciences Conference 2019-12-04 - 2019-12-05

16th Global Cardiovascular Clinical Trialists Forum 2019-12-05 - 2019-12-07

More about us...

Subscribe for corporate news

Follow us on LinkedIn

Follow us on Twitter

Privacy policy

We are proud supporters of World Thrombosis Day. Read more